Netherlands-based Qiagen N.V. (NASDAQ:QGEN) is a leading global provider of sample and assay technologies. The company aims to accelerate growth in 2014 primarily by boosting the global adoption of its QIAsymphony platform and establishing the QuantiFeron-TB platform as the modern gold standard for latent tuberculosis control. In this article I will analyze whether these initiatives are enough for boosting shareholder value amid an extremely tough competitive environment.
Tuberculosis ("TB") is caused by the intracellular pathogen Mycobacterium tuberculosis ("MTB"). In 2011, Qiagen took over Australia's Cellestis, the company that developed QuantiFeron-TB, an FDA-approved interferon-gamma release assay ("IGRA") for the detection of tuberculosis infection. Qiagen has big plans for the QuantiFeron-TB Gold and its variant QuantiFeron-TB Gold In...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|